Skip to main content
Top
Published in: PharmacoEconomics 8/2017

01-08-2017 | Practical Application

How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis

Authors: Laura Bojke, Andrea Manca, Miqdad Asaria, Ronan Mahon, Shijie Ren, Stephen Palmer

Published in: PharmacoEconomics | Issue 8/2017

Login to get access

Abstract

Costs and utilities are key inputs into any cost-effectiveness analysis. Their estimates are typically derived from individual patient-level data collected as part of clinical studies the follow-up duration of which is often too short to allow a robust quantification of the likely costs and benefits a technology will yield over the patient’s entire lifetime. In the absence of long-term data, some form of temporal extrapolation—to project short-term evidence over a longer time horizon—is required. Temporal extrapolation inevitably involves assumptions regarding the behaviour of the quantities of interest beyond the time horizon supported by the clinical evidence. Unfortunately, the implications for decisions made on the basis of evidence derived following this practice and the degree of uncertainty surrounding the validity of any assumptions made are often not fully appreciated. The issue is compounded by the absence of methodological guidance concerning the extrapolation of non-time-to-event outcomes such as costs and utilities. This paper considers current approaches to predict long-term costs and utilities, highlights some of the challenges with the existing methods, and provides recommendations for future applications. It finds that, typically, economic evaluation models employ a simplistic approach to temporal extrapolation of costs and utilities. For instance, their parameters (e.g. mean) are typically assumed to be homogeneous with respect to both time and patients’ characteristics. Furthermore, costs and utilities have often been modelled to follow the dynamics of the associated time-to-event outcomes. However, cost and utility estimates may be more nuanced, and it is important to ensure extrapolation is carried out appropriately for these parameters.
Footnotes
1
This is because many clinical studies are—first and foremost—designed to satisfy the requirements of licensing authorities [e.g. the US Food and Drug Administration (FDA), European Medicines Agency (EMA)] and these do not consider the collection of information relevant to reimbursement authorities.
 
Literature
1.
go back to reference Stafinski T, Menon D, Philippon DJ, et al. Health technology funding decision-making processes around the world. Pharmacoeconomics. 2011;29(6):475–95.CrossRefPubMed Stafinski T, Menon D, Philippon DJ, et al. Health technology funding decision-making processes around the world. Pharmacoeconomics. 2011;29(6):475–95.CrossRefPubMed
3.
go back to reference Kind P, Hardman G, Macran S. UK population norms for EQ-5D: discussion paper 172. York: Centre for Health Economics, University of York; 1999. Kind P, Hardman G, Macran S. UK population norms for EQ-5D: discussion paper 172. York: Centre for Health Economics, University of York; 1999.
4.
go back to reference National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: NICE; 2013. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: NICE; 2013.
5.
go back to reference Salas-Vega S, Bertling A, Mossialos E. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Health Policy. 2016;120(10):1104–14.CrossRefPubMed Salas-Vega S, Bertling A, Mossialos E. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Health Policy. 2016;120(10):1104–14.CrossRefPubMed
7.
go back to reference Sculpher MJ, Claxton K, Drummond M, et al. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15(7):677–87.CrossRefPubMed Sculpher MJ, Claxton K, Drummond M, et al. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15(7):677–87.CrossRefPubMed
8.
go back to reference Collett D. Modelling survival data in medical research. 2nd ed. Boca Raton: Chapman and Hall/CRC; 2003. Collett D. Modelling survival data in medical research. 2nd ed. Boca Raton: Chapman and Hall/CRC; 2003.
10.
go back to reference Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18(3):341–64.CrossRefPubMed Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18(3):341–64.CrossRefPubMed
11.
go back to reference Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
13.
go back to reference Garside R, Pitt M, Somerville M, et al. Surveillance of Barrett’s oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 2006;10(8):1–142, iii–iv. Garside R, Pitt M, Somerville M, et al. Surveillance of Barrett’s oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 2006;10(8):1–142, iii–iv.
14.
go back to reference Wilson J, Connock M, Song F, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess. 2005;9(25):1–142.CrossRefPubMed Wilson J, Connock M, Song F, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess. 2005;9(25):1–142.CrossRefPubMed
15.
go back to reference Bond M, Mealing S, Anderson R, et al. The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. Health Technol Assess. 2009;13(44):1–330.CrossRef Bond M, Mealing S, Anderson R, et al. The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. Health Technol Assess. 2009;13(44):1–330.CrossRef
16.
go back to reference Gospodarevskaya E, Picot J, Cooper K, et al. Ustekinumab for the treatment of moderate to severe psoriasis. Health Technol Assess. 2009;13(Suppl 3):61–6.CrossRefPubMed Gospodarevskaya E, Picot J, Cooper K, et al. Ustekinumab for the treatment of moderate to severe psoriasis. Health Technol Assess. 2009;13(Suppl 3):61–6.CrossRefPubMed
17.
go back to reference Glazener C, Breeman S, Elders A, et al. Clinical effectiveness and cost-effectiveness of surgical options for the management of anterior and/or posterior vaginal wall prolapse: two randomised controlled trials within a comprehensive cohort study—results from the PROSPECT study. Health Technol Assess. 2016;20(95):1–452.CrossRefPubMedPubMedCentral Glazener C, Breeman S, Elders A, et al. Clinical effectiveness and cost-effectiveness of surgical options for the management of anterior and/or posterior vaginal wall prolapse: two randomised controlled trials within a comprehensive cohort study—results from the PROSPECT study. Health Technol Assess. 2016;20(95):1–452.CrossRefPubMedPubMedCentral
18.
go back to reference Madan J, Ades T, Barton P, et al. Consensus decision models for biologics in rheumatoid and psoriatic arthritis: recommendations of a multidisciplinary working party. Rheumatol Ther. 2015;2(2):113–25.CrossRefPubMedPubMedCentral Madan J, Ades T, Barton P, et al. Consensus decision models for biologics in rheumatoid and psoriatic arthritis: recommendations of a multidisciplinary working party. Rheumatol Ther. 2015;2(2):113–25.CrossRefPubMedPubMedCentral
19.
go back to reference Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397–409.CrossRefPubMed Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397–409.CrossRefPubMed
20.
go back to reference Davis S, Stevenson M, Tappenden P, et al. NICE DSU Technical support document 15: cost-effectiveness modelling using pateint-level simulation. Report by the Decision Support Unit. Sheffield: School of Health and Related Research, University of Sheffield; 2014. Davis S, Stevenson M, Tappenden P, et al. NICE DSU Technical support document 15: cost-effectiveness modelling using pateint-level simulation. Report by the Decision Support Unit. Sheffield: School of Health and Related Research, University of Sheffield; 2014.
21.
go back to reference Peasgood T, Brazier J. Is meta-analysis for utility values appropriate given the potential impact different elicitation methods have on values? Pharmacoeconomics. 2015;33(11):1101–5.CrossRefPubMedPubMedCentral Peasgood T, Brazier J. Is meta-analysis for utility values appropriate given the potential impact different elicitation methods have on values? Pharmacoeconomics. 2015;33(11):1101–5.CrossRefPubMedPubMedCentral
22.
go back to reference Peasgood T, Herrmann K, Kanis JA, et al. An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int. 2009;20(6):853–68.CrossRefPubMed Peasgood T, Herrmann K, Kanis JA, et al. An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int. 2009;20(6):853–68.CrossRefPubMed
23.
go back to reference Wyld M, Morton RL, Hayen A, et al. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med. 2012;9(9):e1001307.CrossRefPubMedPubMedCentral Wyld M, Morton RL, Hayen A, et al. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med. 2012;9(9):e1001307.CrossRefPubMedPubMedCentral
24.
go back to reference Bravo Vergel Y, Palmer S, Erhorn S, et al. Adalimumab for the treatment of moderate to severe psoriatic arthritis. Southampton: Health Technol Assess; 2007. Bravo Vergel Y, Palmer S, Erhorn S, et al. Adalimumab for the treatment of moderate to severe psoriatic arthritis. Southampton: Health Technol Assess; 2007.
25.
go back to reference Loveman E, Jones J, Hartwell D, et al. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess. 2010;14(19):1–204.CrossRef Loveman E, Jones J, Hartwell D, et al. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess. 2010;14(19):1–204.CrossRef
26.
go back to reference Turner D, Picot J, Cooper K, et al. Adalimumab for the treatment of psoriasis. Health Technol Assess. 2009;13(Suppl. 2):49–54.PubMed Turner D, Picot J, Cooper K, et al. Adalimumab for the treatment of psoriasis. Health Technol Assess. 2009;13(Suppl. 2):49–54.PubMed
27.
go back to reference Paulden M, Rodgers M, Griffin S, et al. Alitretinoin for the treatment of severe chronic hand eczema. Health Technol Assess. 2010;14(Suppl 1):39–46.CrossRefPubMed Paulden M, Rodgers M, Griffin S, et al. Alitretinoin for the treatment of severe chronic hand eczema. Health Technol Assess. 2010;14(Suppl 1):39–46.CrossRefPubMed
28.
go back to reference Maund E, McKenna C, Sarowar M, et al. Dronedarone for the treatment of atrial fibrillation and atrial flutter. Health Technol Assess 2010;14(Suppl 2):55–62. Maund E, McKenna C, Sarowar M, et al. Dronedarone for the treatment of atrial fibrillation and atrial flutter. Health Technol Assess 2010;14(Suppl 2):55–62.
29.
go back to reference Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15(10):i–xxi, 1–329. Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15(10):i–xxi, 1–329.
30.
go back to reference Hatswell AJ, Pennington B, Pericleous L, et al. Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health Qual Life Outcome. 2014;12:140.CrossRef Hatswell AJ, Pennington B, Pericleous L, et al. Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health Qual Life Outcome. 2014;12:140.CrossRef
31.
go back to reference Kelly E, Stoye G, Vera-Hernandez M. Public hospital spending in England: evidence from National Health Service administrative records. Fiscal Stud. 2016;37(3–4):433–59.CrossRef Kelly E, Stoye G, Vera-Hernandez M. Public hospital spending in England: evidence from National Health Service administrative records. Fiscal Stud. 2016;37(3–4):433–59.CrossRef
32.
go back to reference Asaria M, Doran T, Cookson R. The costs of inequality: whole-population modelling study of lifetime inpatient hospital costs in the English National Health Service by level of neighbourhood deprivation. J Epidemiol Commun Health. 2016;70(10):990–6.CrossRef Asaria M, Doran T, Cookson R. The costs of inequality: whole-population modelling study of lifetime inpatient hospital costs in the English National Health Service by level of neighbourhood deprivation. J Epidemiol Commun Health. 2016;70(10):990–6.CrossRef
33.
go back to reference Epstein DM, Sculpher MJ, Clayton TC, et al. Costs of an early intervention versus a conservative strategy in acute coronary syndrome. Int J Cardiol. 2008;127(2):240–6.CrossRefPubMed Epstein DM, Sculpher MJ, Clayton TC, et al. Costs of an early intervention versus a conservative strategy in acute coronary syndrome. Int J Cardiol. 2008;127(2):240–6.CrossRefPubMed
34.
go back to reference Alva M, Gray A, Mihaylova B, et al. The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity. Health Econ. 2014;23(4):487–500.CrossRefPubMed Alva M, Gray A, Mihaylova B, et al. The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity. Health Econ. 2014;23(4):487–500.CrossRefPubMed
35.
go back to reference Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006;10(31):iii–iv, xiii–xvi, 1–239. Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006;10(31):iii–iv, xiii–xvi, 1–239.
36.
go back to reference Karnon J, Czoski-Murray C, Smith K, et al. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration. Health Technol Assess 2008;12(27):iii–iv, ix–124. Karnon J, Czoski-Murray C, Smith K, et al. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration. Health Technol Assess 2008;12(27):iii–iv, ix–124.
38.
go back to reference National Emphysema Treatment Trial Research Group. Cost effectiveness of lung-volume–reduction surgery for patients with severe emphysema. N Engl J Med. 2003;348:2092–102.CrossRef National Emphysema Treatment Trial Research Group. Cost effectiveness of lung-volume–reduction surgery for patients with severe emphysema. N Engl J Med. 2003;348:2092–102.CrossRef
39.
go back to reference Grant A, Wileman S, Ramsay C, et al. REFLUX Trial Group. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease—a UK collaborative study. The REFLUX Trial. Health Technol Assess. 2008;12(31):1–181.CrossRefPubMed Grant A, Wileman S, Ramsay C, et al. REFLUX Trial Group. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease—a UK collaborative study. The REFLUX Trial. Health Technol Assess. 2008;12(31):1–181.CrossRefPubMed
40.
go back to reference McKenna C, McDaid C, Suekarran S, et al. Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis. Health Technol Assess 2009; 13(24): iii–iv, ix–xi, 1–90. McKenna C, McDaid C, Suekarran S, et al. Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis. Health Technol Assess 2009; 13(24): iii–iv, ix–xi, 1–90.
41.
go back to reference de Vries EF, Rabelink TJ, van den Hout WB. Modelling the cost-effectiveness of delaying end-stage renal disease. Nephron. 2016;133(2):89–97.CrossRefPubMed de Vries EF, Rabelink TJ, van den Hout WB. Modelling the cost-effectiveness of delaying end-stage renal disease. Nephron. 2016;133(2):89–97.CrossRefPubMed
42.
go back to reference Keating CL, Dixon JB, Moodie ML, et al. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diabetes Care. 2009;32(4):567–74.CrossRefPubMedPubMedCentral Keating CL, Dixon JB, Moodie ML, et al. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diabetes Care. 2009;32(4):567–74.CrossRefPubMedPubMedCentral
43.
go back to reference Harrison DA, Prabhu G, Grieve R, et al. Risk Adjustment In Neurocritical care (RAIN)—prospective validation of risk prediction models for adult patients with acute traumatic brain injury to use to evaluate the optimum location and comparative costs of neurocritical care: a cohort study. Health Technol Assess 2013;17(23):vii–viii, 1–350. Harrison DA, Prabhu G, Grieve R, et al. Risk Adjustment In Neurocritical care (RAIN)—prospective validation of risk prediction models for adult patients with acute traumatic brain injury to use to evaluate the optimum location and comparative costs of neurocritical care: a cohort study. Health Technol Assess 2013;17(23):vii–viii, 1–350.
44.
go back to reference Stevenson M, Lloyd-Jones M, Papaioannou D. Vitamin K to prevent fractures in older women: a systematic review and economic evaluation. Health Technol Assess. 2009;13(45):iii–xi, 1–134. Stevenson M, Lloyd-Jones M, Papaioannou D. Vitamin K to prevent fractures in older women: a systematic review and economic evaluation. Health Technol Assess. 2009;13(45):iii–xi, 1–134.
45.
go back to reference Henriksson M, Epstein DM, Palmer SJ, et al. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. Heart. 2008;94(6):717–23.CrossRefPubMed Henriksson M, Epstein DM, Palmer SJ, et al. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. Heart. 2008;94(6):717–23.CrossRefPubMed
46.
go back to reference Main C, Bojke L, Griffin S, et al. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technol Assess. 2006;10(9):1–132.CrossRef Main C, Bojke L, Griffin S, et al. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technol Assess. 2006;10(9):1–132.CrossRef
47.
go back to reference Batty A, Winn B, Pericleous L, et al. A comparison of general population and patient utility values for advanced melanoma. European Society for Medical Oncology. Value Health. 2012;15:A277–A575. Batty A, Winn B, Pericleous L, et al. A comparison of general population and patient utility values for advanced melanoma. European Society for Medical Oncology. Value Health. 2012;15:A277–A575.
48.
go back to reference Kind P, Hardman G, Macran S. UK population norms for EQ-5D. York Centre for Health Economics discussion paper. York: University of York; 1999. p. 172. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. York Centre for Health Economics discussion paper. York: University of York; 1999. p. 172.
49.
go back to reference Peek GJ, Clemens F, Elbourne D, et al. CESAR: conventional ventilatory support vs extracorporeal membrane oxygenation for severe adult respiratory failure. BMC Health Serv Res. 2006;6:163. Peek GJ, Clemens F, Elbourne D, et al. CESAR: conventional ventilatory support vs extracorporeal membrane oxygenation for severe adult respiratory failure. BMC Health Serv Res. 2006;6:163.
50.
go back to reference Jackson CH, Thompson SG, Sharples LD. Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Ser A Stat Soc. 2009;172(2):383–404.CrossRefPubMedPubMedCentral Jackson CH, Thompson SG, Sharples LD. Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Ser A Stat Soc. 2009;172(2):383–404.CrossRefPubMedPubMedCentral
51.
go back to reference Ara R, Wailoo A. NICE DSU technical support document 12: the use of health state utility values in decision models. Sheffield: School of Health and Related Research, University of Sheffield; 2011. Ara R, Wailoo A. NICE DSU technical support document 12: the use of health state utility values in decision models. Sheffield: School of Health and Related Research, University of Sheffield; 2011.
52.
go back to reference van Duin MJ, Conde R, Wijnen B, et al. The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá. Epub: Expert Rev Pharmacoecon Outcome Res; 2016. van Duin MJ, Conde R, Wijnen B, et al. The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá. Epub: Expert Rev Pharmacoecon Outcome Res; 2016.
53.
go back to reference Briggs AH, Parfrey PS, Khan N, et al. Analyzing health-related quality of life in the EVOLVE trial: the joint impact of treatment and clinical events. Med Decis Making. 2016;36(8):965–72.CrossRefPubMed Briggs AH, Parfrey PS, Khan N, et al. Analyzing health-related quality of life in the EVOLVE trial: the joint impact of treatment and clinical events. Med Decis Making. 2016;36(8):965–72.CrossRefPubMed
54.
go back to reference Oostenbrink JB, Al MJ, Rutten-van Mölken MP. Methods to analyse cost data of patients who withdraw in a clinical trial setting. Pharmacoeconomics. 2003;21(15):1103–12.CrossRefPubMed Oostenbrink JB, Al MJ, Rutten-van Mölken MP. Methods to analyse cost data of patients who withdraw in a clinical trial setting. Pharmacoeconomics. 2003;21(15):1103–12.CrossRefPubMed
55.
go back to reference Rappange DR, van Baal PH, van Exel NJ, et al. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics. 2008;26(10):815–30.CrossRefPubMed Rappange DR, van Baal PH, van Exel NJ, et al. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics. 2008;26(10):815–30.CrossRefPubMed
56.
go back to reference Morton A, Adler AI, Bell D, et al. Unrelated future costs and unrelated future benefits: reflections on NICE guide to the methods of technology appraisal. Health Econ. 2016;25(8):933–8.CrossRefPubMed Morton A, Adler AI, Bell D, et al. Unrelated future costs and unrelated future benefits: reflections on NICE guide to the methods of technology appraisal. Health Econ. 2016;25(8):933–8.CrossRefPubMed
57.
go back to reference van Baal P, Meltzer D, Brouwer W. Future costs, fixed healthcare budgets, and the decision rules of cost-effectiveness analysis. Health Econ. 2016;25(2):237–48.CrossRefPubMed van Baal P, Meltzer D, Brouwer W. Future costs, fixed healthcare budgets, and the decision rules of cost-effectiveness analysis. Health Econ. 2016;25(2):237–48.CrossRefPubMed
58.
go back to reference Claxton K, Palmer S, Longworth L, et al. Uncertainty, evidence and irrecoverable costs: informing approval, pricing and research decisions for health technologies. CHE discussion paper 69. York: Centre for Health Economics; 2011. Claxton K, Palmer S, Longworth L, et al. Uncertainty, evidence and irrecoverable costs: informing approval, pricing and research decisions for health technologies. CHE discussion paper 69. York: Centre for Health Economics; 2011.
59.
go back to reference Griffin S, Claxton KP, Palmer SJ, et al. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ. 2011;20(2):212–24.CrossRefPubMed Griffin S, Claxton KP, Palmer SJ, et al. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ. 2011;20(2):212–24.CrossRefPubMed
Metadata
Title
How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis
Authors
Laura Bojke
Andrea Manca
Miqdad Asaria
Ronan Mahon
Shijie Ren
Stephen Palmer
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 8/2017
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-017-0512-6

Other articles of this Issue 8/2017

PharmacoEconomics 8/2017 Go to the issue